MedWatch

Genmab postpones crucial cancer candidate decision following Abbvie exit

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.

Photo: PR / Genmab

The collaboration between Genmab, a Danish biotech company, and US-based Abbvie entails the development of a string of molecules – which was recently cut a little shorter when Abbvie decided to discontinue the shared efforts on one candidate in particular.

Duohexabody-CD37 (Gen3009), a treatment candidate for B-cell malignancies that typically form in white blood cells and include most non-Hodgkin lymphomas, was developed using the Duohexabody technology platform, and is now left solely in Genmab’s charge.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs